Preclinical study demonstrates that agonistic antibody CCM5.01 suppresses colon cancer cell growth via CEACAM1-L signaling, highlighting a novel therapeutic avenue for resistant tumors.
Key Points
To assess the inhibitory efficacy of the agonistic anti-CEACAM1 antibody CCM5.01 against colorectal cancer cells and determine how the ratio of long to short CEACAM1 isoforms modulates this response.
Treated human colorectal cancer cell lines (HT-29, LOVO, and HCT-116) with the agonistic monoclonal antibody CCM5.01.
Conducted proliferation and downstream signaling assays in cells transfected with either long (L) or short (S) CEACAM1 isoforms.
Assessed therapeutic response and growth inhibition using both 2D cell cultures and 3D tumor spheroid models.
CCM5.01 induced dose-dependent inhibition of cell proliferation in CEACAM1-positive colorectal cancer cell lines.
High expression of the CEACAM1-L isoform triggered growth arrest and apoptosis, whereas high CEACAM1-S expression promoted cellular activity.
Isoform-dependent suppression of tumor growth by CCM5.01 was similarly demonstrated in 3D spheroid models.